Best Growth Hormone Peptides

Growth hormone peptides fall into two functional categories: GHRH (growth hormone-releasing hormone) analogs and GHRPs (growth hormone-releasing peptides). GHRH analogs like CJC-1295 and tesamorelin work by amplifying the natural GH pulse — they stimulate the pituitary gland to produce more growth hormone during each secretory event. GHRPs like ipamorelin, GHRP-2, GHRP-6, and hexarelin work through a different receptor (the ghrelin/GHS receptor) to initiate GH pulses independently of GHRH signaling.

The critical insight is that these two pathways are synergistic. When a GHRH analog and a GHRP are administered together, the resulting GH release is substantially greater than the sum of either compound alone — often 3 to 5 times higher than a single agent. This is why the most common research protocols pair one compound from each class. The rankings below consider each compound individually, but stacking remains the most effective strategy for maximizing growth hormone output.

1. Ipamorelin — Cleanest GHRP, Selective GH Release

Ipamorelin is a pentapeptide growth hormone secretagogue that acts on the ghrelin receptor to stimulate pituitary GH release. What sets ipamorelin apart from other GHRPs is its exceptional selectivity — it produces a clean, dose-dependent rise in growth hormone without significantly elevating cortisol, prolactin, or aldosterone. This selectivity makes it the most side-effect-friendly GHRP available and the standard recommendation for individuals new to GH peptides.

In clinical studies, ipamorelin produced GH elevations comparable to GHRP-6 at equivalent doses but without the appetite stimulation or hormonal disruption. It preserves normal pulsatile GH secretion patterns, meaning the pituitary is not being forced into continuous output — an important factor for long-term use. Ipamorelin does not appear to desensitize the GH axis with chronic administration, unlike hexarelin.

Research protocols typically use 100–300mcg per injection, administered 2–3 times daily via subcutaneous injection. For optimal results, ipamorelin is almost always paired with a GHRH analog such as CJC-1295 No DAC (Mod GRF 1-29), which amplifies the GH pulse it initiates. Timing around sleep and post-training windows aligns with natural GH secretion peaks.

2. CJC-1295 No DAC (Mod GRF 1-29) — GHRH Analog for Natural GH Pulses

CJC-1295 without DAC, also known as Modified GRF 1-29 or Mod GRF, is a truncated and modified analog of growth hormone-releasing hormone. It consists of the first 29 amino acids of GHRH with four amino acid substitutions that protect it from rapid enzymatic degradation, extending its functional half-life to approximately 30 minutes. It amplifies GH output by acting directly on GHRH receptors in the anterior pituitary.

The key advantage of the No DAC version is that it preserves physiological pulsatile GH release. Each injection produces a defined GH pulse that rises and falls naturally, rather than creating the sustained GH elevation seen with the DAC version. This pulsatile pattern more closely mimics endogenous GH secretion and is believed to be healthier for long-term use, as continuous GH elevation can cause insulin resistance and other complications.

Research protocols use 100mcg per injection, administered 2–3 times daily alongside a GHRP like ipamorelin. The combination of Mod GRF 1-29 plus ipamorelin is the most widely used GH peptide stack in research settings due to its strong synergy, clean side effect profile, and preservation of natural GH pulsing. Injections are typically timed before sleep, upon waking, and post-training.

3. CJC-1295 DAC — Extended Half-Life GHRH

CJC-1295 with DAC (Drug Affinity Complex) is the same GHRH analog as Mod GRF 1-29 but conjugated with a lysine linker that binds to albumin in the bloodstream. This albumin binding extends the half-life from roughly 30 minutes to 6–8 days, creating sustained GH elevation from a single injection. Clinical studies demonstrated that a single dose of CJC-1295 DAC increased mean GH levels by 2 to 10 times baseline for up to 6 days, with IGF-1 levels remaining elevated for 9–11 days.

The convenience of less frequent dosing — typically once or twice per week — is the primary advantage. However, the sustained GH elevation means the pituitary is being continuously stimulated rather than producing discrete pulses. This creates a less physiological pattern that may increase the risk of side effects like water retention, joint stiffness, and insulin resistance with long-term use. Some researchers argue that pulsatile release is more effective for fat loss and tissue repair than sustained elevation.

Research protocols use 1–2mg injected subcutaneously once or twice weekly. CJC-1295 DAC can be combined with GHRPs, though the continuous GHRH stimulation partially negates the pulse-initiating benefit of a GHRP. It is best suited for individuals prioritizing dosing convenience over precise physiological mimicry.

4. Tesamorelin — FDA-Approved GHRH, Most Clinically Validated

Tesamorelin is a 44-amino-acid GHRH analog and the only FDA-approved growth hormone secretagogue on this list. Approved under the brand name Egrifta for HIV-associated lipodystrophy, it has the most rigorous clinical validation of any GH peptide, with multiple randomized controlled trials demonstrating its efficacy and safety. Tesamorelin stimulates the pituitary to release GH in a pulsatile fashion, raising IGF-1 levels by approximately 50–100% from baseline.

Clinical trials showed tesamorelin reduced visceral adipose tissue by 15–18% over 26 weeks while preserving lean mass — a profile that makes it particularly attractive for body recomposition goals. Beyond fat loss, research suggests tesamorelin improves cognitive function in older adults and may reduce liver fat in non-alcoholic fatty liver disease. Its FDA approval means it has a well-characterized safety profile from large-scale human studies.

Standard dosing is 2mg daily via subcutaneous injection. Tesamorelin may raise blood glucose and IGF-1 levels, requiring monitoring. It is a prescription medication and typically more expensive than investigational GH peptides. For individuals who prioritize clinical evidence and regulatory approval, tesamorelin is the strongest choice among GH secretagogues.

5. GHRP-2 — Strong GH Release, More Potent Than Ipamorelin

GHRP-2 (pralmorelin) is a synthetic hexapeptide growth hormone secretagogue that produces stronger GH release than ipamorelin on a per-dose basis. It acts on the ghrelin receptor in the pituitary and hypothalamus, triggering robust GH pulses. In head-to-head comparisons, GHRP-2 elicits higher peak GH levels than ipamorelin, making it attractive for individuals seeking maximum GH output from a single compound.

The trade-off for greater potency is reduced selectivity. GHRP-2 mildly elevates cortisol and prolactin — not to a degree that typically causes clinical symptoms, but meaningfully more than ipamorelin. It also stimulates appetite through ghrelin mimicry, though less dramatically than GHRP-6. These hormonal effects are generally considered acceptable in research contexts, especially when the goal is maximizing GH elevation for recovery, lean mass, or anti-aging protocols.

Research protocols use 100–300mcg per injection, 2–3 times daily. Like all GHRPs, GHRP-2 is most effective when paired with a GHRH analog such as CJC-1295 No DAC. It does not appear to desensitize the GH axis with chronic use at standard doses. GHRP-2 occupies a middle ground between ipamorelin's cleanliness and hexarelin's raw potency.

6. GHRP-6 — Strong GH Release + Appetite Stimulation

GHRP-6 is one of the earliest synthetic growth hormone-releasing peptides, acting on the ghrelin receptor to stimulate potent GH release. Its defining characteristic — and what separates it from other GHRPs — is the significant appetite stimulation it produces through ghrelin mimicry. Within 20 minutes of injection, most users experience intense hunger that persists for 30–60 minutes. This makes GHRP-6 uniquely useful for individuals who struggle to eat enough to support muscle growth.

GH release from GHRP-6 is comparable to GHRP-2, producing robust elevations that are stronger than ipamorelin but less potent than hexarelin. Like GHRP-2, it raises cortisol and prolactin mildly — enough to be measurable on bloodwork but generally not enough to produce symptoms at standard research doses. The appetite effect is mediated through the same ghrelin receptor pathway that drives GH release, so the two effects cannot be separated.

Research protocols use 100–300mcg per injection, 2–3 times daily via subcutaneous injection. GHRP-6 is best suited for hard-gainers or individuals in caloric surplus phases who benefit from increased appetite. For those seeking GH elevation without appetite stimulation, ipamorelin or GHRP-2 are better choices. Stacking with CJC-1295 No DAC produces the expected GHRH/GHRP synergy.

7. Hexarelin — Most Potent GHRP by GH Output

Hexarelin is the most potent growth hormone-releasing peptide by peak GH output. It produces the highest acute GH spike of any GHRP in comparative studies, making it the strongest single-agent option for maximizing growth hormone levels. Beyond GH release, hexarelin has demonstrated notable cardioprotective effects in research — it binds to cardiac receptors (CD36) independent of GH signaling, reducing cardiac fibrosis and protecting against ischemic damage in animal models.

The primary limitation of hexarelin is desensitization. With chronic daily use, the GH response progressively diminishes over 4–8 weeks as the pituitary downregulates its responsiveness. This makes hexarelin poorly suited for sustained long-term protocols without cycling — typically 4 weeks on followed by 2–4 weeks off. Additionally, hexarelin raises cortisol and prolactin more than any other GHRP, which may be problematic for individuals sensitive to these hormones.

Research protocols use 100–200mcg per injection, 2–3 times daily. Due to desensitization, hexarelin is often used in short bursts for acute GH elevation rather than as a chronic secretagogue. Its cardioprotective properties have generated research interest independent of GH release. For sustained GH protocols, ipamorelin or GHRP-2 are more practical choices. Hexarelin pairs synergistically with GHRH analogs like CJC-1295 No DAC during active use phases.

Growth Hormone Peptides Comparison Table

How to Choose the Right Growth Hormone Peptide

The most important decision is whether you need a standalone compound or a synergistic stack. For most research goals — recovery, body recomposition, anti-aging, and sleep improvement — the combination of a GHRH analog plus a GHRP produces the best results. The standard pairing of CJC-1295 No DAC with ipamorelin is the most widely recommended starting point because it maximizes GH output with minimal hormonal disruption. This stack preserves natural pulsatile secretion and does not desensitize with chronic use.

If you prioritize clinical validation and have access to a prescription, tesamorelin offers the strongest evidence base and FDA oversight. For individuals who want stronger GH output and tolerate mild cortisol and prolactin elevation, GHRP-2 replaces ipamorelin in the stack. GHRP-6 is best reserved for those who specifically need appetite stimulation. Hexarelin suits short-term protocols where maximum acute GH elevation is the goal, but its desensitization limits long-term utility. CJC-1295 DAC is ideal when dosing convenience matters more than physiological pulsing. Always start with the cleanest option and escalate only if needed.

Frequently Asked Questions